Table 1.

Baseline clinical characteristics (N = 193)

Gender	Female	46.6%
Median age	63 years (range 31–89)
Age > 65 years	40.9%
Age > 70 years	18.1%
Stage at diagnosis	Locally/locally advanced Metastatic	20.2% 79.8%
Primary location	Head	58.0%
	Body	20.2%
	Tail	16.1%
	Multiple sides	3.6%
	Unknown	2.1%
Histology	Adenocarcinoma	97.9%
	Other (N = 4)	2.1%
Grading	G1	3.1%
	G2	45.6%
	G3	18.7%
	Unknown*	32.6%
Bilirubin > 1.5ULN	16.1%
Initial CA 19–9 (median)	565 U/ml (range 1–463, 600U/ml)
Primary resection in curative intent	N = 24	12.4%
	R0	23.2%
	R1	17.9%
	R2	1.8%
	Rx	57.2%
Adjuvant/additive chemotherapy	19	79.2% of curative resected
Palliative surgery	N = 32	16.6%
Primary stenting	N = 21	10.9%
Median disease free survival after resection (95% CI)		13 months (10.1–15.9)
Sites of metastasis	Liver	56.5%
	Lymph nodes	23.8%
	Lung	10.9%
	Peritoneum	22.3%
	Other	14.5%
Follow-up time (range)	135.0 months (98.9–232.2)
Number of cases lost to follow-up	N = 21 (10.9%)
Number of death	N = 171 (88.6%)

ULN upper limit of normal, CA 19–9 carbohydrate antigen 19–9, CI confidence interval

*Diagnosis by cytology